Payment overview · 2025
General Payments
$138.69
7 reported records · 6 companies
Healthcare provider profile · identity verified
Patrick G Wetovick, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · COZAD, NE · NPI 1588680953
Verified facts
What the public records show
CMS Open Payments records show Patrick G Wetovick, M.D. received $138.69 in general payments during 2025 across 7 reported records.
Integra LifeSciences Corporation accounted for 35.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $48.96 | 35.3% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.43 | 17.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.42 | 13.3% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $17.23 | 12.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.88 | 10.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.77 | 10.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $138.69 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Integra Normalized: integra |
Device | Integra LifeSciences Corporation | $48.96 | 2 | 2025 |
Source payment records
|
|||||
| Integra Dermal Regeneration Template Normalized: integra dermal regeneration template |
Device | Integra LifeSciences Corporation | $48.96 | 2 | 2025 |
Source payment records
|
|||||
| PRIMATRIX Normalized: primatrix |
Device | Integra LifeSciences Corporation | $48.96 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.43 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.42 | 1 | 2025 |
Source payment records
|
|||||
| Intracept Normalized: intracept |
Device | Boston Scientific Corporation | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 505 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 449 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 354 | 61 |
| Lisinopril | Lisinopril | 295 | 49 |
| Metformin Hcl | Metformin Hcl | 250 | 37 |
| Omeprazole | Omeprazole | 195 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 192 | 27 |
| Furosemide | Furosemide | 190 | 26 |
| Losartan Potassium | Losartan Potassium | 186 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 178 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 174 | 34 |
| Potassium Chloride | Potassium Chloride | 169 | 25 |
| Xarelto | Rivaroxaban | 153 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 150 | 21 |
| Warfarin Sodium | Warfarin Sodium | 146 | 12 |
| Famotidine | Famotidine | 143 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 142 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 132 | 22 |
| Carvedilol | Carvedilol | 119 | 20 |
| Simvastatin | Simvastatin | 115 | 24 |
| Gabapentin | Gabapentin | 111 | 21 |
| Eliquis | Apixaban | 110 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 110 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 12 |
| Candesartan Cilexetil | Candesartan Cilexetil | 97 | 14 |
| Tramadol Hcl | Tramadol Hcl | 97 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 96 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 95 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 87 | 13 |
| Finasteride | Finasteride | 82 | 13 |
| Donepezil Hcl | Donepezil Hcl | 79 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 79 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 11 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 62 | 62 |
| Dutasteride | Dutasteride | 58 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 56 | suppressed |
| Prednisone | Prednisone | 55 | 29 |
| Chlorthalidone | Chlorthalidone | 54 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 53 | 16 |
| Enalapril Maleate | Enalapril Maleate | 52 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 15 |
| Risperidone | Risperidone | 49 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 48 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | suppressed |
| Spironolactone | Spironolactone | 48 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Loperamide | Loperamide Hcl | 47 | suppressed |
| Allopurinol | Allopurinol | 46 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 45 | suppressed |
| Sotalol | Sotalol Hcl | 44 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 42 | suppressed |
| Ezetimibe | Ezetimibe | 42 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | suppressed |
| Glimepiride | Glimepiride | 41 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 39 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 39 | suppressed |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Ozempic | Semaglutide | 37 | suppressed |
| Vascepa | Icosapent Ethyl | 35 | suppressed |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Jardiance | Empagliflozin | 34 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Bumetanide | Bumetanide | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 27 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 26 | 11 |
| Alprazolam | Alprazolam | 26 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 15 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 12 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Cefadroxil | Cefadroxil | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Sunosi | Solriamfetol Hcl | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 11 | 11 |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $138.69 · 7 records | Integra LifeSciences Corporation | BREZTRI, Cologuard Collection Kit, FREESTYLE LIBRE 3, Integra, Integra Dermal Regeneration Template, Intracept, Ozempic, PRIMATRIX, Rybelsus | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error